COGT Cogent Biosciences (COGT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001622229
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
197
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $245.5K priced
What the filings say about COGT
Insiders, 180 days
-$1.7M net sold
1 seller · 100% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.7M
1 notice
Cogent Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Cogent Biosciences, Inc. insiders sold a net $1.7M of stock across 12 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1339.7% of the 3,161 shares held after it.
- No other insider sold within 30 days.
- 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Morris Arlene sold about $1.6M of COGT under a 10b5-1 plan on Aug 27, 2026; 197 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- No other insider sold within 30 days.
- 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Morris Arlene sold about $118.7K of COGT under a 10b5-1 plan on Aug 27, 2026; 197 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (3 buys, 1 sale), the last on Jan 22, 2026.
- +43.6% median (+53.5% mean) 90-day return after 3 previous buys.
- The trade is 127.2% of the 5,503,418 shares held after it.
- No other insider sold within 30 days.
- 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fairmount Funds Management LLC sold about $242.6M of COGT on Mar 31, 2026, the largest insider sale at the company on our record; 197 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 10, 2025.
- +43.6% median (+53.5% mean) 90-day return after 3 previous buys.
- The trade is 63.6% of the 5,503,418 shares held after it.
- 4 other insiders sold within 30 days.
- 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fairmount Funds Management LLC sold about $127.4M of COGT on Jan 22, 2026, the largest insider sale at the company on our record; 4 other insiders sold within 30 days and 197 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 59.4% of the 109,398 shares held after it.
- 4 other insiders sold within 30 days.
- 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Kearns Evan sold about $2.5M of COGT on Dec 26, 2025, the largest insider sale at the company on our record; 4 other insiders sold within 30 days and 197 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.7M over 180 days
-$1.7M over 90 days
below 68% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
197 funds bought in last quarter
more than 90% of Pharma & Biotech
Revenue
-65.0% year over year
below 83% of Pharma & Biotech
Margin
-4179.1% net margin
below 96% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.3% of the float short (float per yahoo 2026-10-26) · 8.1 days to cover · settled 2026-09-30
more than 75% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch COGT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+108.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns COGT: institutional holders (13F)
13F holdings, latest reported quarter
25,681,174 sh
$993.9M
17,352,646 sh
$671.5M
8,072,411 sh
$312.4M
7,412,330 sh
$286.9M
6,964,919 sh
$269.5M
Congress trades in COGT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
COGT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
ARLENE MORRIS
Filed 2026-08-27
$1.7M
COGT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
F/m Emerald Life Sciences Innovation ETF
$7.9M position · as of 2026-05-31
7.5%
Tema Oncology ETF
$7.2M position · as of 2026-05-31
4.1%
Fidelity Advisor Biotechnology Fund
$71.4M position · as of 2026-07-31
3.2%
Fidelity Disruptive Medicine ETF
$1.2M position · as of 2026-05-31
2.9%
Lord Abbett Micro-Cap Growth Fund
$5.8M position · as of 2026-07-31
2.7%
Miller Convertible Total Return ETF
$309.2K position · as of 2026-07-31
2.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 6 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
2 active
2
Phase 2
2 active
1
Phase 3
1 active
2
Not applicable
0 active
2
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$27.8M
$116.8M
$8.9M
+314%
+21%
2024
$4.9M
$11.9M
$2.3M
-9%
-9%
2023
$7.9M
-$201.5K
$3.0M
-31%
-8%
2022
$4.4M
$9.8M
$1.9M
+35%
-11%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.7M sold by insiders over 180 days, 197 funds added last quarter, $1.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
COGT financials
Revenue growth
-65.0%
XBRL, annual
Net margin
-4179.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.9M
four quarters, 2020-01-01 to 2020-12-31
Revenue, TTM COGT
| FY Dec 2025 | $7.9M |
| FY Dec 2024 | $7.9M |
| FY Dec 2023 | $7.9M |
| FY Dec 2022 | $7.9M |
| FY Dec 2021 | $7.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
-4,792%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM COGT
| FY Dec 2025 | -4,179% |
| FY Dec 2024 | -3,251% |
| FY Dec 2023 | -2,445% |
| FY Dec 2022 | -1,782% |
| FY Dec 2021 | -918.2% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$309.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM COGT
| FY Dec 2025 | -$266.0M |
| FY Dec 2024 | -$208.4M |
| FY Dec 2023 | -$156.4M |
| FY Dec 2022 | -$125.5M |
| FY Dec 2021 | n/a |
| Jun 2026 | -$77.6M |
| Mar 2026 | -$87.3M |
| Dec 2025 | -$79.9M |
| Sep 2025 | -$64.4M |
| Jun 2025 | -$54.7M |
| Mar 2025 | -$67.1M |
| Dec 2024 | -$60.7M |
| Sep 2024 | -$52.3M |
At each fiscal year end
Single quarter
Debt to equity
0.42x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity COGT
| FY Dec 2025 | 0.35x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.42x |
| Mar 2026 | 0.37x |
| Dec 2025 | 0.35x |
| Sep 2025 | 0.15x |
| Jun 2025 | 0.28x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.38x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt COGT
| FY Dec 2025 | -1.19x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1.38x |
| Mar 2026 | -1.28x |
| Dec 2025 | -1.19x |
| Sep 2025 | -5.56x |
| Jun 2025 | -5.32x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-109.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity COGT
| FY Dec 2025 | -73.7% |
| FY Dec 2024 | -99.5% |
| FY Dec 2023 | -74.9% |
| FY Dec 2022 | -59.7% |
| FY Dec 2021 | -32.2% |
| Jun 2026 | -109.7% |
| Mar 2026 | -85.7% |
| Dec 2025 | -73.7% |
| Sep 2025 | -95.4% |
| Jun 2025 | -107.6% |
| Mar 2025 | -84.0% |
| Dec 2024 | -99.5% |
| Sep 2024 | -78.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-68.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets COGT
| FY Dec 2025 | -52.0% |
| FY Dec 2024 | -79.8% |
| FY Dec 2023 | -62.6% |
| FY Dec 2022 | -52.6% |
| FY Dec 2021 | -29.9% |
| Jun 2026 | -68.0% |
| Mar 2026 | -59.7% |
| Dec 2025 | -52.0% |
| Sep 2025 | -72.7% |
| Jun 2025 | -80.6% |
| Mar 2025 | -70.9% |
| Dec 2024 | -79.8% |
| Sep 2024 | -65.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital COGT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-78.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed COGT
| FY Dec 2025 | -58.2% |
| FY Dec 2024 | -100.8% |
| FY Dec 2023 | -75.8% |
| FY Dec 2022 | -60.5% |
| FY Dec 2021 | -33.4% |
| Jun 2026 | -78.5% |
| Mar 2026 | -67.1% |
| Dec 2025 | -58.2% |
| Sep 2025 | -88.6% |
| Jun 2025 | -98.8% |
| Mar 2025 | -85.6% |
| Dec 2024 | -100.8% |
| Sep 2024 | -79.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing COGT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.4B
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value COGT
| FY Dec 2025 | $5.0B |
| FY Dec 2024 | $763.4M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $6.7B |
| Mar 2026 | $6.2B |
| Dec 2025 | $5.0B |
| Sep 2025 | $1.9B |
| Jun 2025 | $733.8M |
| Mar 2025 | $556.0M |
| Dec 2024 | $763.4M |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-5.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield COGT
| FY Dec 2025 | -5.3% |
| FY Dec 2024 | -24.2% |
| FY Dec 2023 | -30.9% |
| FY Dec 2022 | -15.5% |
| FY Dec 2021 | n/a |
| Jun 2026 | -4.7% |
| Mar 2026 | -4.6% |
| Dec 2025 | -5.3% |
| Sep 2025 | -12.3% |
| Jun 2025 | -28.7% |
| Mar 2025 | -32.7% |
| Dec 2024 | -24.2% |
| Sep 2024 | -16.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing COGT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$333.4M | -$275.9M | -$208.1M | -$147.8M |
| Net income | -$328.9M | -$255.9M | -$192.4M | -$140.2M |
| EPS (diluted) | -2.16 | -1.94 | -1.94 | -1.73 |
| Operating cash flow | -$264.4M | -$207.8M | -$153.6M | -$118.6M |
| Cash | $312.0M | $98.2M | $53.2M | $139.9M |
| Long-term debt | $222.9M | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
COGT Stock Sonar score 6/7 axes
Find similar shapesCompareCOGT ranks highest on institutional and government (90th percentile) and financial health (42nd), and lowest on insider conviction (1st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
COGT filings, in plain words
Are Cogent Biosciences insiders buying or selling COGT?
In the 180 days to 2026-10-28, Cogent Biosciences insiders were net sellers, a net $1.7M across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of COGT?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $1.7M of stock; the latest, by ARLENE MORRIS, was filed 2026-08-27.
Read the full summary
In the 180 days to 2026-10-28, Cogent Biosciences insiders were net sellers of COGT, a net $1.7M across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $1.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
